Skip to Main content Skip to Navigation
Journal articles

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth

Abstract : Chemotherapeutic agents are widely used for cancer treatment. In addition to their direct cytotoxic effects, these agents harness the host's immune system, which contributes to their antitumor activity. Here we show that two clinically used chemotherapeutic agents, gemcitabine (Gem) and 5-fluorouracil (5FU), activate the NOD-like receptor family, pyrin domain containing-3 protein (Nlrp3)-dependent caspase-1 activation complex (termed the inflammasome) in myeloid-derived suppressor cells (MDSCs), leading to production of interleukin-1β (IL-1β), which curtails anticancer immunity. Chemotherapy-triggered IL-1β secretion relied on lysosomal permeabilization and the release of cathepsin B, which bound to Nlrp3 and drove caspase-1 activation. MDSC-derived IL-1β induced secretion of IL-17 by CD4+ T cells, which blunted the anticancer efficacy of the chemotherapy. Accordingly, Gem and 5FU exerted higher antitumor effects when tumors were established in Nlrp3−/− or Casp1−/− mice or wild-type mice treated with interleukin-1 receptor antagonist (IL-1Ra). Altogether, these results identify how activation of the Nlrp3 inflammasome in MDSCs by 5FU and Gem limits the antitumor efficacy of these chemotherapeutic agents.
Document type :
Journal articles
Complete list of metadatas

https://hal.archives-ouvertes.fr/hal-00919371
Contributor : Sandrine Pyon <>
Submitted on : Monday, December 16, 2013 - 4:20:31 PM
Last modification on : Thursday, November 12, 2020 - 9:42:04 AM

Identifiers

Citation

Melanie Bruchard, Gregoire Mignot, Valentin Derangere, Fanny Chalmin, Angélique Chevriaux, et al.. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nature Medicine, Nature Publishing Group, 2013, 19, pp.57 - 64. ⟨10.1038/nm.2999⟩. ⟨hal-00919371⟩

Share

Metrics

Record views

411